William T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical Officer
Prominent heart failure cardiologist Dr. William Abraham to play pivotal role in the advancement of the Carillon Mitral Contour System® to heart failure patients with FMR.
Cardiac Dimensions®, a leader in transcatheter therapies for heart failure, announced today the appointment of William T. Abraham, MD, as Chief Medical Officer. A globally recognized expert in heart failure and device-based therapies, Dr. Abraham will help lead the company’s clinical and regulatory strategies as it advances toward U.S. regulatory approval and continues to expand European commercial sales of the Carillon Mitral Contour System®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903095354/en/
Dr. William T. Abraham, Chief Medical Officer at Cardiac Dimensions
Dr. Abraham most recently served as the Chief Medical Officer at V-Wave Ltd., where he led the U.S. pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson. Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University, where he was the Director of the Division of Cardiovascular Medicine for more than 15 years, and has published over 650 peer-reviewed papers. He is internationally known for his leadership in advancing heart failure treatments, including cardiac resynchronization therapy, remote hemodynamic monitoring, and transcatheter valve repair. Dr. Abraham has also served as national or global principal investigator on more than 50 multicenter trials, including important trials within the mitral valve space.
“We are delighted to welcome Dr. Abraham to the Cardiac Dimensions leadership team,” said Rick Wypych, President and CEO of Cardiac Dimensions. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this much-needed therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal U.S. landmark study – The EMPOWER Trial.”
“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” said Dr. Abraham. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favorable atrial and ventricular remodeling, symptom improvement, and a excellent safety profile – even in patients with proportionate MR who are often excluded from other therapies.”
The Carillon Mitral Contour System has received CE Mark and is available for sale in Europe and other countries that recognize CE Mark.
About the CarillonMitral Contour System®
The Carillon Mitral Contour System is a minimally invasive device designed to treat heart failure patients with functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. It is commercially available in Europe, as well as other countries, and is currently being studied in the U.S. pivotal EMPOWER Trial.
About the EMPOWER Trial
The EMPOWER Trial is a prospective, randomized, sham-controlled pivotal study evaluating the safety and effectiveness of the Carillon Mitral Contour System® in heart failure patients with mild to severe functional mitral regurgitation. Designed to enroll up to 300 patients across leading U.S. and international centers, the trial aims to support FDA approval by demonstrating the Carillon therapy’s potential to improve symptoms, cardiac structure, and long-term outcomes in a broad heart failure population.
About Cardiac Dimensions®
Cardiac Dimensions is committed to addressing the rapidly growing patient population suffering from heart failure with functional mitral regurgitation. With decades of clinical experience and thousands of patients treated worldwide, the company’s Carillon device is uniquely positioned as a durable therapy designed to treat early and late-stage patients, improve symptoms and reverse disease progression. Learn more at www.cardiacdimensions.com.
CAUTION: In the United States, the Carillon System is an investigational device, limited by federal law to investigational use.
Cardiac Dimensions, Carillon, and Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions.
© 2025 Cardiac Dimensions. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903095354/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
84% of Businesses Report Rising Network Outages Over Past Two Years3.9.2025 14:00:00 CEST | Press release
Ongoing rise of network outages has cost over a third of organizations between $1M and $5M in the last year, putting data centers at risk of significant disruption Nearly nine in ten organizations have experienced an increase in network outages over the past two years, with more than a quarter reporting increases of 25% to 50%, according to new research from Opengear, a Digi International company (NASDAQ, DGII, (www.digi.com). The rise in outages has cost more than a third of businesses between $1m and $5m in the past year alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903508317/en/ Network outages are on the rise — 84% of businesses report more disruptions in the past two years, with over a third losing $1M–$5M in the last year, according to new research from Opengear. Over half of organizations also noted a 10-24% increase in outages over the two-year timeframe. The survey, designed to identify critical pain poin
MSCI Launches Private Credit Factor Model to Bring Transparency to Rapidly Growing Asset Class3.9.2025 14:00:00 CEST | Press release
Expanding MSCI’s multi-asset risk modeling suite, the new tool analyzes private credit risk within a total portfolio context MSCI Inc. (NYSE: MSCI) launched a Private Credit Factor Model to help investors overcome the lack of transparency in the asset class and better assess the long-term risks it presents in their overall portfolios. As investors continue to increase their allocations to the private credit market, they face a critical challenge: A lack of data and insights into their investments can obscure their view of risks of private investments within the context of their total portfolio. Over the past decade the explosive growth in private credit, driven by investors’ search for yield and structural shifts in capital markets, has outpaced the tools needed to manage it. And institutional investors such as pension funds are being asked by plan participants, boards and other stakeholders to shed light on these often-opaque assets. Designed to address these challenges, the Private C
SBC Medical to Participate in the H.C. Wainwright Conference & Emerging Growth Conference in September 20253.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, announced that it will participate in several prominent investor conferences throughout September 2025. SBC Medical will deliver large presentations and conduct one-on-one meetings with institutional investors. Below is a summary of the Company’s participation in investor conferences: H.C. Wainwright Conference Main Speaker: Hikaru Fukui (Head of IR) Date: Sep 8, 2025 Link: https://hcwevents.com/annualconference/ Emerging Growth Conference (Large Presentation) Main Speaker: Yuya Yoshida (Director, CFO, COO) Date: Sep 25, 2025, from 9:05 - 9:35 AM Eastern time. Link: https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=sbc About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment cent
NuScale Proudly Supports TVA and ENTRA1 Energy Announcement of Landmark 6-Gigawatt Small Module Reactor (SMR) Deployment Program3.9.2025 13:59:00 CEST | Press release
Represents the Largest SMR Deployment in U.S. HistoryInitiative Advances President Trump’s Vision for U.S. Energy Security and American Leadership in Advanced Nuclear Technologies NuScale Power Corporation (NYSE: SMR), the industry-leading provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology, today announced its strong support for ENTRA1 Energy’s American landmark agreement with the Tennessee Valley Authority (TVA) to deploy up to 6 gigawatts of NuScale SMR capacity across TVA’s seven-state service region—the largest SMR deployment program in U.S. history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903569182/en/ This historic program is expected to deliver enough carbon-free, baseload electricity to power at least the equivalent of the entire Dallas-Fort Worth metropolitan area, which is essential at a time when sectors such as hyperscale datacenters, artificial intelligence (
Hilton and Small Luxury Hotels of the World™ Celebrate One-Year Anniversary of Exclusive Partnership, Now With More than 450 Hotels3.9.2025 13:01:00 CEST | Press release
More than 450 new hotels to dream about and book. 12 new countries to travel to with Hilton. A new world of luxury travel. In just one year, Hilton's (NYSE: HLT) exclusive partnership with Small Luxury Hotels of the World (SLH) has grown exponentially, adding on average more than one SLH property every week, dramatically expanding Hilton’s luxury offerings and creating new ways for Hilton Honors members to dream and redeem their Points around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903685115/en/ In just one year, Hilton's exclusive partnership with Small Luxury Hotels of the World (SLH) has grown exponentially, adding on average more than one SLH property every week, dramatically expanding Hilton’s luxury offerings and creating new ways for Hilton Honors members to dream and redeem their Points around the world. (Photo: Small Luxury Hotels of the World) The addition of SLH to Hilton’s luxury portfolio –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom